フルテキストURL ijerph16_5_00690.pdf
著者 Toyama, Naoki| Ekuni, Daisuke| Taniguchi-Tabata, Ayano| Kataoka, Kota| Yamane-Takeuchi, Mayu| Fujimori, Kohei| Kobayashi, Terumasa| Fukuhara, Daiki| Irie, Koichiro| Azuma, Tetsuji| Iwasaki, Yoshiaki| Morita, Manabu|
キーワード bruxism cohort study malocclusion underweight young adults
発行日 2019-02-26
出版物タイトル International Journal of Environmental Research and Public Health
16巻
5号
出版者 MDPI
開始ページ 690
ISSN 1660-4601
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 © 2019 by the authors
論文のバージョン publisher
PubMed ID 30813621
DOI 10.3390/ijerph16050690
Web of Sience KeyUT 000462664200015
関連URL isVersionOf https://doi.org/10.3390/ijerph16050690
JaLCDOI 10.18926/AMO/53560
フルテキストURL 69_4_237.pdf
著者 Nanba, Shintarou| Ikeda, Fusao| Fujioka, Shin-ichi| Araki, Yasuyuki| Takaguchi, Kouichi| Hashimoto, Noriaki| Seki, Hiroyuki| Takaki, Akinobu| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
抄録 The effectiveness of extending treatment duration as response guided therapy was previously reported for chronic hepatitis C (CHC) genotype 1, but is still controversial for genotype 2. The present study is a retrospective cohort study to investigate the effectiveness of extending treatment duration in therapy with pegylated interferon and ribavirin for patients with CHC genotype 2 by focusing on the timing at which patients obtained undetectable HCV RNA. A total of 306 patients who obtained undetectable HCV RNA by week 24 of treatment and completed 24 weeks of treatment were enrolled. Rapid virological response (RVR) to standard therapy was achieved by 122 patients (51オ), and 89オ of them obtained sustained virological response (SVR), while 69オ of non-RVR patients achieved SVR. Non-RVR patients with undetectable HCV RNA at week 8, and insufficient adherence<80オ pegylated interferon and ribavirin during the first 24 weeks, significantly improved their SVR rate by extended therapy. Among patients receiving extended therapy, drug adherences did not differ between SVR and non-SVR patients, indicating that extending treatment duration might compensate for insufficient antiviral effects due to insufficient drug adherences. This finding might be useful in creating a guideline for extending treatment duration for patients with CHC genotype 2.
キーワード hepatitis C virus interferon genotype 2 response-guided therapy
Amo Type Original Article
発行日 2015-08
出版物タイトル Acta Medica Okayama
69巻
4号
出版者 Okayama University Medical School
開始ページ 237
終了ページ 244
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26289915
Web of Sience KeyUT 000365519100007
JaLCDOI 10.18926/AMO/53520
フルテキストURL 69_3_137.pdf
著者 Seki, Hiroyuki| Ikeda, Fusao| Nanba, Shintaro| Moritou, Yuki| Takeuchi, Yasuto| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Nakamura, Minoru| Yamamoto, Kazuhide|
抄録 A predictive marker of the rapid progression to hepatic failure is desired for patients with asymptomatic primary biliary cirrhosis (aPBC). We performed a systematic cohort analysis of 101 patients diagnosed as having aPBC and the rapid progression to liver failure in some, by focusing on cholestasis. Cholestasis was assessed by aberrant keratin7 (K-7) expressions in the patientsʼ hepatocytes. Intralobular expressions of K-7 were found in 9 of the 101 patients. The grades of K-7 expression were significantly associated with the levels of alanine aminotransferase, alkaline phosphatase, and total bilirubin at the time of diagnosis, but not with bile duct loss or cholestasis. Stepwise logistic regression analysis revealed that high grades of K-7 expression correlated positively with high levels of total bilirubin. During the follow-up period, 8 patients developed jaundice, and the mean period until the development of jaundice was 5.2 years. The proportional hazards models for the risk of developing jaundice identified a high grade of aberrant K-7 expression in hepatocytes as the only significant risk factor. Aberrant K-7 expression in hepatocytes can be used as an additional marker to predict rapid progression to liver failure in patients with aPBC at the time of diagnosis.
キーワード primary biliary cirrhosis keratin 7 hepatic failure
Amo Type Original Article
発行日 2015-06
出版物タイトル Acta Medica Okayama
69巻
3号
出版者 Okayama University Medical School
開始ページ 137
終了ページ 144
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26101189
Web of Sience KeyUT 000356903000002
JaLCDOI 10.18926/AMO/52894
フルテキストURL 68_5_263.pdf
著者 Namba, Shihoko| Miyake, Kayoko| Ikeda, Fusao| Hazama, Tomoko| Hitobe, Yu| Yamasaki, Noriko| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
抄録 Nursing support might help patients with chronic hepatitis C (CHC) remain in good mental and physical condition during interferon (IFN) therapy. However, the effects of nursing support have not been studied adequately in this context. This case-control study evaluated the effects of nursing support during IFN therapy. Twenty-four CHC patients who received pegylated IFN and ribavirin were enrolled. Nurses advised patients on the maintenance of their mental and physical condition at weekly visits, based on the results of written questionnaires. An additional 24 patients who received IFN therapy without nursing support and who were matched for age, sex, platelet count, viral serogroup and IFN regimen were selected with propensity score matching as controls. The patients with nursing support during IFN therapy achieved higher sustained virological responses (79%) than those without nursing support (58%). Adherence to the IFN and ribavirin regimens at 24 weeks of therapy were slightly higher in the patients with nursing support than those without it, but these differences were not statistically significant. Adherence to ribavirin after 24 weeks of therapy was significantly higher in those with nursing support than those without it (93% and 66%, p=0.045). These results suggested that nursing support services could contribute to the virological responses of CHC patients by promoting drug-regimen adherence.
キーワード chronic hepatitis C nursing support interferon therapy
Amo Type Original Article
発行日 2014-10
出版物タイトル Acta Medica Okayama
68巻
5号
出版者 Okayama University Medical School
開始ページ 263
終了ページ 268
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 25338482
Web of Sience KeyUT 000343269300002
JaLCDOI 10.18926/AMO/52898
フルテキストURL 68_5_291.pdf
著者 Tsuzaki, Ryuichiro| Takaki, Akinobu| Yagi, Takahito| Ikeda, Fusao| Koike, Kazuko| Iwasaki, Yoshiaki| Shiraha, Hidenori| Miyake, Yasuhiro| Sadamori, Hiroshi| Shinoura, Susumu| Umeda, Yuzo| Yoshida, Ryuichi| Nobuoka, Daisuke| Utsumi, Masashi| Nakayama, Eiichi| Fujiwara, Toshiyoshi| Yamamoto, Kazuhide|
抄録 It is not known how the immune system targets hepatitis C virus (HCV)-infected HLA-mismatched hepatocytes under immune-suppressed conditions after orthotopic liver transplantation (OLT). In addition, the relationship between the HCV-specific immune response and IL28B variants as predictors of HCV clearance has not been well-characterized. We determined the IL28B polymorphisms for 57 post-OLT HCV carriers, and we assessed the HCV-specific immune responses by measuring the peripheral blood mononuclear cell-derived HCV-specific interferon-gamma (IFN-γ) response using an enzyme-linked immunospot assay. At 1-3 years after OLT, patients with no active hepatitis showed higher total spots on the immunospot assay. At>3 years after OLT, patients with resolved HCV showed higher levels of core, NS3, NS5A, and total spots compared to the chronic hepatitis patients. The IL28B major genotype in the donors correlated with higher spot counts for NS5A and NS5B proteins at 1-3 years after OLT. In the post-OLT setting, the HCV-specific immune response could be strongly induced in patients with no active hepatitis with an IL28B major donor or sustained virological response. Strong immune responses in the patients with no active hepatitis could only be maintained for 3 years and diminished later. It may be beneficial to administer IFN treatment starting 3 years after OLT, to induce the maximum immunological effect.
キーワード interferon gamma ELISPOT assay single nucleotide polymorphisms dendritic cell CD4 T cell
Amo Type Original Article
発行日 2014-10
出版物タイトル Acta Medica Okayama
68巻
5号
出版者 Okayama University Medical School
開始ページ 291
終了ページ 302
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 25338486
Web of Sience KeyUT 000343269300006
関連URL http://ousar.lib.okayama-u.ac.jp/metadata/53129
JaLCDOI 10.18926/AMO/52139
フルテキストURL 68_1_17.pdf
著者 Moritou, Yuki| Ikeda, Fusao| Iwasaki, Yoshiaki| Baba, Nobuyuki| Takaguchi, Kouichi| Senoh, Tomonori| Nagano, Takuya| Takeuchi, Yasuto| Yasunaka, Tetsuya| Ohnishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Yamamoto, Kazuhide|
抄録 The impact of hepatic steatosis on interferon therapy for patients with chronic hepatitis C (CHC) has been associated with single-nucleotide polymorphisms (SNP) of IL28B, patatin-like phospholipase domain-containing protein 3 (PNPLA3), and low-density lipoprotein (LDL) receptor. Whether this holds true for Japanese patients, however, remains unresolved. The present study prospectively enrolled 226 Japanese patients with CHC, and investigated the impact of hepatic steatosis and its related SNPs, including rs8099917 of IL28B, rs738409 of PNPLA3, and rs14158 of LDL receptor, on outcomes of peg-interferon and ribavirin therapy. In multivariate logistic regression analysis, significant factors affecting the severity of hepatic steatosis were high body mass index and the minor alleles of IL28B SNP (p=0.020 and 0.039, respectively). The risk alleles of PNPLA3 SNP also showed weak association (p=0.059). Severe steatosis and the minor alleles of IL28B SNP were significantly associated with null or partial virological response in patients with HCV genotype 1, as were female gender, and low LDL cholesterol (p=0.049, and <0.001, respectively). The SNP genotype of PNPLA3 and LDL receptor did not have a significant impact on therapeutic outcomes. With respect to the SNP sites examined, the SNP of PNPLA3 has a weak association with severe hepatic steatosis, but not with the outcome of interferon therapy.
キーワード hepatic steatosis genetic polymorphism interferon HCV
Amo Type Original Article
発行日 2014-02
出版物タイトル Acta Medica Okayama
68巻
1号
出版者 Okayama University Medical School
開始ページ 17
終了ページ 22
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2014 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 24553484
Web of Sience KeyUT 000331592800003
著者 Matsushita, Hiroshi| Ikeda, Fusao| Iwasaki, Yoshiaki| Seki, Hiroyuki| Nanba, Shintaro| Takeuchi, Yasuto| Moritou, Yuki| Yasunaka, Tetsuya| Onishi, Hideki| Miyake, Yasuhiro| Takaki, Akinobu| Nouso, Kazuhiro| Yamamoto, Kazuhide|
発行日 2014-02
出版物タイトル Journal of Gastroenterology and Hepatology
29巻
2号
資料タイプ 学術雑誌論文
著者 Moritou, Yuki| Ikeda, Fusao| Takeuchi, Yasuto| Seki, Hiroyuki| Nanba, Shintaro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2014-02
出版物タイトル Journal of Clinical Microbiology
52巻
2号
資料タイプ 学術雑誌論文
著者 Takeuchi, Yasuto| Ikeda, Fusao| Moritou, Yuki| Hagihara, Hiroaki| Yasunaka, Tetsuya| Kuwaki, Kenji| Miyake, Yasuhiro| Ohnishi, Hideki| Nakamura, Shinichiro| Shiraha, Hidenori| Takaki, Akinobu| Iwasaki, Yoshiaki| Nouso, Kazuhiro| Yamamoto, Kazuhide|
発行日 2013-03
出版物タイトル Journal of Gastroenterology
48巻
3号
資料タイプ 学術雑誌論文
著者 Nishimura, Mamoru| Takaki, Akinobu| Tamaki, Naofumi| Maruyama, Takayuki| Onishi, Hideki| Kobayashi, Sayo| Nouso, Kazuhiro| Yasunaka, Tetsuya| Koike, Kazuko| Hagihara, Hiroaki| Kuwaki, Kenji| Nakamura, Shinichiro| Ikeda, Fusao| Iwasaki, Yoshiaki| Tomofuji, Takaaki| Morita, Manabu| Yamamoto, Kazuhide|
発行日 2013-01-30
出版物タイトル Hepatology Research
43巻
10号
資料タイプ 学術雑誌論文
著者 Mizutani, Shinsuke| Ekuni, Daisuke| Furuta, Michiko| Tomofuji, Takaaki| Irie, Koichiro| Azuma, Tetsuji| Kojima, Azusa| Nagase, Jun| Iwasaki, Yoshiaki| Morita, Manabu|
発行日 2012-09
出版物タイトル Journal of Clinical Periodontology
39巻
9号
資料タイプ 学術雑誌論文
著者 Tatsukawa, Masashi| Takaki, Akinobu| Shiraha, Hidenori| Koike, Kazuko| Iwasaki, Yoshiaki| Kobashi, Haruhiko| Fujioka, Shin-Ichi| Sakaguchi, Kohsaku| Yamamoto, Kazuhide|
発行日 2011-10-21
出版物タイトル BMC Cancer
11巻
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/43825
フルテキストURL 65_1_11.pdf
著者 Kuwaki, Kenji| Nouso, Kazuhiro| Kobayashi, Yoshiyuki| Nakamura, Shinichiro| Ito, Yoichi M.| Iwadou, Shouta| Hagihara, Hiroaki| Yasunaka, Tetsuya| Toshimori, Junichi| Miyatake, Hirokazu| Miyoshi, Kenji| Onishi, Hideki| Miyake, Yasuhiro| Shoji, Bon| Takaki, Akinobu| Shiraha, Hidenori| Iwasaki, Yoshiaki| Kobashi, Haruhiko| Yamamoto, Kazuhide|
抄録 The purpose of this study was to build a prognostic model of hepatocellular carcinoma (HCC) using time-dependent covariates to re-evaluate the prognosis at any stage of the disease. The subjects were consecutive HCC patients who were treated at our institute between 1995 and 2007. We constructed time-fixed and time-dependent prognostic models with a training group (n=336) and compared the prognostic abilities between conventional Cancer of the Liver Italian Program (CLIP) scores, Japan Integrated Staging (JIS) scores, an Okuda classification, and our prognostic models in the testing group (n=227) with the c-index. The time-dependent prognostic model consisted of main tumor size, tumor number, portal vein invasion, distant metastasis, alpha-fetoprotein, des-gamma-carboxy prothrombin (DCP), bilirubin, and albumin and the weighted scores were set for each factor depending on the hazard ratio for the prognosis. The prognostic index was determined by summing the scores. The c-index values for the CLIP scores, JIS scores, Okuda classification, and our time-dependent model were 0.741, 0.727, 0.609, and 0.870, respectively. These results indicate that our time-dependent model can estimate the prognosis of HCC more precisely than traditional time-fixed models and can be used to re-predict the prognosis of HCC.
キーワード hepatocellular carcinoma humans prognosis proportional hazards models time factors
Amo Type Original Article
発行日 2011-02
出版物タイトル Acta Medica Okayama
65巻
1号
出版者 Okayama University Medical School
開始ページ 11
終了ページ 19
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2011 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 21339791
Web of Sience KeyUT 000287620500002
著者 Shoji, Bon| Ikeda, Fusao| Fujioka, Shin-ichi| Kobashi, Haruhiko| Yasunaka, Tetsuya| Miyake, Yasuhiro| Shiraha, Hidenori| Takaki, Akinobu| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2010-11
出版物タイトル Journal of Gastroenterology
45巻
11号
資料タイプ 学術雑誌論文
著者 Kubota, Junichi| Ikeda, Fusao| Terada, Ryo| Kobashi, Haruhiko| Fujioka, Shin-ichi| Okamoto, Ryoichi| Baba, Shinsuke| Morimoto, Youichi| Ando, Masaharu| Makino, Yasuhiro| Taniguchi, Hideaki| Yasunaka, Tetsuya| Miyake, Yasuhiro| Iwasaki, Yoshiaki| Yamamoto, Kazuhide|
発行日 2009-09
出版物タイトル Journal of Gastroenterology
44巻
9号
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/32914
フルテキストURL fulltext.pdf
著者 Miyake, Yasuhiro| Iwasaki, Yoshiaki| Ishikawa, Shin| Tatsukawa, Masashi| Nawa, Toru| Kato, Jun| Takaki, Akinobu| Kobashi, Haruhiko| Sakaguchi, Kohsaku| Shiratori, Yasushi|
抄録 We report herein a case with acute hepatitis due to hepatitis B virus genotype Ae, concurrent with amebic colitis. A 39-year-old homosexual Japanese man was admitted to our hospital with jaundice. Laboratory tests showed an elevation of transaminase and positivity for hepatitis B surface antigen and IgM-type antibody to hepatitis B core antigen. The hepatitis B virus genotype was determined to be Ae. Furthermore, a mud-like stool with blood and mucous had sometimes been noted during the past 3 years, and amebic colitis was shown by colonofi berscopy during hospitalization. The patient was diagnosed with acute hepatitis B, concurrent with amebic colitis, and was successfully treated with lamivudine and metronidazole. In Japanese patients with acute hepatitis B virus genotype A infection, homosexual activity tends to be high. Furthermore, in Japanese homosexual men, amebiasis has been increasing. Thus, in Japanese patients with acute hepatitis B, a determination of genotype should be performed in order to investigate the route of transmission of hepatitis B virus, and a search for amebiasis should be performed in patients with acute hepatitis due to hepatitis B virus genotype A. Furthermore, education of homosexual men regarding hepatitis B virus, hepatitis B virus vaccination, and amebiasis is urgently required.
キーワード hepatitis B virus genotype homosexual amebic colitis lamivudine
Amo Type Case Report
発行日 2007-02
出版物タイトル Acta Medica Okayama
61巻
1号
出版者 Okayama University Medical School
開始ページ 35
終了ページ 39
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 17332840
Web of Sience KeyUT 000244432400005
JaLCDOI 10.18926/AMO/30729
フルテキストURL fulltext.pdf
著者 Ohta, Takeyuki| Sakaguchi, Kohsaku| Fujiwara, Akiko| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Makino, Yasuhiro| Araki, Yasuyuki| Shiratori, Yasushi|
抄録 <p>This study was conducted to develop a simple surrogate index comprised of routinely available laboratory tests to reflect the histological fibrosis stage. Clinical characteristics and laboratory data from 368 and 249 consecutive patients with chronic hepatitis C, a training cohort and a validation cohort, respectively, were retrospectively evaluated. Platelet (Plt) count and albumin (Alb) level contributed to the discrimination of the respective fibrosis stages. We derived the fi brosis index (FI), FI = 8.0-0.01 x Plt (10 multiply 3/microliter) - Alb (g/dl), from a multiple regression model. FI significantly correlated with the histological fibrosis stage in both the initial and validation cohort at p=0.691 and p=0.661, respectively (Spearman's rank correlation coefficient, p&#60;0.0001). The sensitivity and positive predictive value of FI at a cutoff value &#60; 2.10 for predicting fibrosis stage F0-1 were 66.8% and 78.8% in the initial cohort and 68.5% and 63.6% in the validation cohort, respectively. Corresponding values of FI at a cutoff value &#62;- 3.30 for the prediction of F4 were 67.7% and 75.0% in the initial cohort and 70.8% and 81.0% in the validation cohort. The fibrosis index comprised of platelet count and albumin level reflected the histological fibrosis stage in patients with chronic hepatitis C.</p>
キーワード albumin level chronic hepatitis C fi brosis index fi brosis stage platelet count
Amo Type Article
発行日 2006-04
出版物タイトル Acta Medica Okayama
60巻
2号
出版者 Okayama University Medical School
開始ページ 77
終了ページ 84
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16680183
Web of Sience KeyUT 000237001900002
JaLCDOI 10.18926/AMO/31969
フルテキストURL fulltext.pdf
著者 Piao, Cheng-Yu| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Fujio, Kozo| Kaneyoshi, Toshihiko| Araki, Yasuyuki| Hashimoto, Kuniaki| Senoh, Tomonori| Terada, Ryo| Nishida, Tomohiro| Kobashi, Haruhiko| Sakaguchi, Kohsaku| Shiratori, Yasushi|
抄録 <p>Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P= 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required.</p>
キーワード liver failure Child-Pughscore recurrence survival resistant mutant
Amo Type Article
発行日 2005-10
出版物タイトル Acta Medica Okayama
59巻
5号
出版者 Okayama University Medical School
開始ページ 217
終了ページ 224
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16286955
Web of Sience KeyUT 000232835600006
著者 Hanafusa, Tadashi| Shinji, Toshiyuki| Shiraha, Hidenori| Nouso, Kazuhiro| Iwasaki, Yoshiaki| Yumoto, Eichiro| Ono, Toshiro| Koide, Norio|
発行日 2005-01-20
出版物タイトル BMC Cancer
5巻
資料タイプ 学術雑誌論文
JaLCDOI 10.18926/AMO/32825
フルテキストURL fulltext.pdf
著者 Nakajima, Hirofumi| Shimomura, Hiroyuki| Iwasaki, Yoshiaki| Ikeda, Fusao| Umeoka, Fumi| Chengyu, Piao| Taniguchi, Hideaki| Ohnishi, Yasuhiro| Takagi, Shin-jiro| Fujioka, Shin-ichi| Shiratori, Yasushi|
抄録 <p>To improve the efficacy of interferon (IFN) treatment for chronic hepatitis C, we have proposed the twice-daily administration of IFN-beta as a promising induction therapy. In this study, we demonstrated differences between the clearance of circulating HCV-RNA and the induction of anti-viral actions during the first 2 weeks of treatment. Nine patients with a high viral load and genotype 1b were randomly assigned to 3 groups: group A received 3MU of IFN-beta twice a day at intervals of 5 and 19 h; group B received 3MU of IFN-beta twice a day at intervals of 10 and 14 h; group C received 6MU of IFN-alpha once a day with ribavirin. The expression of OAS2, PKR, and MxA in peripheral blood mononuclear cells (PBMCs) were quantified by real-time polymerase chain reaction method. The viral clearance showed a bi-phasic pattern, and those in the second phase of groups A and B were significantly steeper than that of group C. The peak level of OAS2 during the first phase was correlated with the first phase decay. The MxA expression tended to be higher in group A and B than in group C. The expression of these 3 proteins tended to decrease at day 6 in group C, but increase in groups A and B. These might make differences in the viral decay during the second phase</p>
キーワード chronic hepatitis C(CHC) interferon(IFN)beta hepatitis C virus(HCV)dynamics antiviral actions real time PCR
Amo Type Article
発行日 2003-10
出版物タイトル Acta Medica Okayama
57巻
5号
出版者 Okayama University Medical School
開始ページ 217
終了ページ 225
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 14679399
Web of Sience KeyUT 000186186000002